The Biostatistics Core Facility (BCF) of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) provides collaborative statistical support to UCCCC investigators engaged in clinical, basic, and population sciences research. The facility is currently staffed by five PhD statisticians and one masters-level statistician in addition to the Scientific and Technical Directors. The services provided by the BCF include collaboration in the formation of study designs and data analysis plans; protocol development, randomization, and statistical analysis for Phase I, Phase II, and Phase III clinical trials; assistance in the design and analysis of retrospective and prospective observational studies; and statistical collaboration on basic science and animal research projects. The BCF interacts closely with the Cancer Clinical Trials Office (CCTO) and the UCCCC Information Technology (IT) group on database development and data management procedures to ensure a high level of data quality for clinical trials and other studies conducted within the Cancer Center. The BCF also works with the Bioinformatics Core Facility (BiCF) to ensure that investigators have access to the broad spectrum of potential analytic services required for specific studies. Clarification of specific aims and hypotheses to be tested, specification of primary, secondary, and correlative endpoints, sample-size (power) calculations, and development of data analysis plans are major areas of activity during the design phase of a study. During the conduct of a study, the BCF performs interim analyses and generates accrual and adverse event reports. Upon completion of the study, the BCF performs final statistical analyses and assists in the preparation of manuscripts for publication. BCF members also conduct statistical methodological research in support of research projects conducted within the UCCCC. During 2013-2016, members of the BCF co-authored 84 collaborative publications with UCCCC investigators and published 16 statistical methods papers stimulated by studies conducted within the UCCCC and to advance the field of oncological research. The BCF also works with UCCCC investigators in the development of new grant applications. Presently, BCF staff are engaged in active support of nine NIH/NCI-funded grants (with committed percent effort), and are co-investigators on 10 cancer-related grants pending review. BCF members serve on two key UCCCC committees that comprise the Protocol Review and Monitoring System, i.e., the Clinical Trials Review Committee (CTRC) and the Scientific Accrual Monitoring (SAM) Committee. Participation on these committees ensures that all protocols and cancer-related research projects undergo rigorous biostatistical review and patient enrollment to ongoing studies is proceeding at an optimal pace. Finally, the BCF participates in teaching and mentoring activities to foster better understanding of statistical methods among UCCCC researchers. Thus, the BCF plays a major role in accomplishing the scientific aims and objectives of the UCCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-45
Application #
9904503
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Webber, Jemma L; Zhang, Jie; Massey, Alex et al. (2018) Collaborative repressive action of the antagonistic ETS transcription factors Pointed and Yan fine-tunes gene expression to confer robustness in Drosophila. Development 145:
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5
Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Maron, Steven B; Alpert, Lindsay; Kwak, Heewon A et al. (2018) Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 8:696-713

Showing the most recent 10 out of 668 publications